Launching the project of Japanese regenerative medical treatment for cancer - AsiaNewPower
LANGUAGE

Launching the project of Japanese regenerative medical treatment for cancer

The two sides will step by step transfer regenerative medical technology with the strict regulations and standards  of the Ministry of Health Vietnam and Japan; applying in the treatment of some incurable diseases such as cardiovascular disease, diabetes, cancer … and application in beauty.

 

 

 

 

 

 

 

 

 

 The signing ceremony of cooperation project of Japanese Regenerative Medicine.

On 26th August 2017, in Japan, Japan-Vietnam International Joint Stock Company (JVI-Vietnam) and Helene Stem Cell Center (Japan) signed a cooperative project of Japan-Vietnam Regenerative Medicine.

Speaking at the signing ceremony, Director of Helene- Matsuoka Takaaki said: “The number of Vietnamese clients for stem cell therapy at the Center is about 13% and this number is growing year by year. Therefore, we determined that the transfer of regenerative medical technology in Vietnam is an important development goal, and that JVI is a reliable partner to help us achieve that goal. “

JVI representative, PhD. Dinh Ngoc Hai, President of JVI said, “We want to share JVI’s future development strategy in the field of medicine. With the project of regenerative medicine in Japan, in the near future, Vietnamese people can access advanced medical technology in the world at reasonable cost.

Speaking at the signing ceremony, VCCI President Vu Tien Loc said: “The Japanese medical project promises to be an important development for the regenerative medical industry in Vietnam. This is a high technology sector and is being encouraged by the government. “

On this basis, the two sides will set up a new legal company, including leading doctors and experts in the field of regenerative medicine in Japan and Vietnam, step by step transferring regenerative medical technology based on strict standards and regulations of the Ministry of Health in Vietnam and Japan.

The goal of the project is to transfer the regenerative medical technologies for cancer prevention and treatment, followed by technologies for rejuvenation and treatment of other diseases. New legal company will invest in infrastructure, build a system of regenerative medical centers with international standards in major cities to transfer and exploit technology the most effectively.

Regenerative medicine is a field that studies the mechanism of replacement or regeneration of human cells, tissues and organs in order to restore or establish normal functioning. Japan has the world’s leading regenerative medical development with two biomedical Nobel Prizes in 2012 and 2016 by Prof. Shina Yamanaka and Prof. Yoshinori Ohsumi for his work on reprogramming and self-replicating mechanism of the cell.

Stem cell research in Japan is strongly developed and applied in medicine to prevent and treat incurable diseases such as cancer, cardiovascular disease, diabetes, Parkinson’s disease, osteoarthritis. As well as applications in beauty, rejuvenation, improving health and prolong human life.